| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Kuebler Christopher A serves as a Director at NKTR and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 0 buys and 21 sells. Those positions are worth an estimated $10.8M at current prices.
Historically, Kuebler Christopher A's trades have earned a middling insider score of 58/100 across 4 rated trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +4.6%.
The biggest single holding is WAT (~$7.4M) as Director. The recent filings there lean toward selling, a net 45,626 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 22, 2017 | NKTR Nektar Therapeutics | Director | Sell | 4,000 | $21.86 | $87,440.00 | -9.0% | |
| Aug 8, 2017 | WAT Waters Corp /de/ | Director | Sale+OE | 3,500 | $179.67 | $628,845.00 | -19.6% | |
| Apr 5, 2017 | NKTR Nektar Therapeutics | Director | Sale+OE | 15,000 | $21.88 | $328,200.00 | -29.7% | |
| Sep 16, 2016 | NKTR Nektar Therapeutics | Director | Sale+OE | 7,500 | $19.13 | $143,475.00 | -21.4% | |
| May 4, 2016 | WAT Waters Corp /de/ | Director | Sale+OE | 4,000 | $129.88 | $519,520.00 | -19.5% | |
| Dec 4, 2015 | NKTR Nektar Therapeutics | Director | Sale+OE | 15,000 | $15.82 | $237,300.00 | -42.9% | |
| Nov 23, 2015 | WAT Waters Corp /de/ | Director | Sale+OE | 4,000 | $133.17 | $532,680.00 | -24.0% | |
| Jan 13, 2015 | NKTR Nektar Therapeutics | Director | Sale+OE | 15,000 | $16.00 | $240,000.00 | -42.9% |